Mitoxantrone repression of astrocyte activation: Relevance to multiple sclerosis

Brain Research

Volumn 1473, Issue , 2012, Pages 236-241

  Burns, Samuel A ^a   Lee Archer, R ^a   Chavis, Janet A ^a   Tull, Cameron A ^b   Hensley, Lori L ^b   Drew, Paul D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b OUACHITA BAPTIST UNIVERSITY   (United States)

Author keywords

Astrocyte; Chemokine; Cytokine; Mitoxantrone; Nitric oxide; T cell

Indexed keywords

C REACTIVE PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; LIPOPOLYSACCHARIDE; MITOXANTRONE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; ASTROCYTE; CELL ACTIVATION; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ASTROCYTES; CELL SURVIVAL; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MICE; MICE, INBRED C57BL; MITOXANTRONE; MULTIPLE SCLEROSIS;

ANIMALIA;

EID: 84865503557     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.07.054     Document Type: Article

References (30)

1. S.W. Barger, J.A. Chavis, and P.D. Drew Dehydroepiandrosterone inhibits microglial nitric oxide production in a stimulus-specific manner J. Neurosci. Res. 62 2000 503 509
2. E. Bettelli Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells Nature 441 2006 235 238
3. J. De Keyser, E. Zeinstra, and E. Frohman Are astrocytes central players in the pathophysiology of multiple sclerosis? Arch. Neurol. 60 2003 132 136
4. Y. Dong, and E.N. Benveniste Immune function of astrocytes Glia 36 2001 180 190
5. C. Farina, F. Aloisi, and E. Meinl Astrocytes are active players in cerebral innate immunity Trends Immunol. 28 2007 138 145
6. M.E. Fox, and P.J. Smith Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone Cancer Res. 50 1990 5813 5818
7. J.E. Holley Astrocyte characterization in the multiple sclerosis glial scar Neuropathol. Appl. Neurobiol. 29 2003 434 444
8. C. Holmes Systemic inflammation and disease progression in Alzheimer disease Neurology 73 2009 768 774
9. J. Koeller, and M. Eble Mitoxantrone: a novel anthracycline derivative Clin. Pharm. 7 1988 574 581
10. C.L. Langrish IL-23 drives a pathogenic T cell population that induces autoimmune inflammation J. Exp. Med. 201 2005 233 240
11. S. Levine, and A. Saltzman Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone J. Neuroimmunol. 13 1986 175 181
12. F.D. Lublin Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone Clin. Immunol. Immunopathol. 45 1987 122 128
13. P.R. Mangan Transforming growth factor-beta induces development of the T(H)17 lineage Nature 441 2006 231 234
14. R. Martin, and H.F. McFarland Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis Crit. Rev. Clin. Lab. Sci. 32 1995 121 182
15. K.D. McCarthy, and J. de Vellis Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissue J. Cell Biol. 85 1980 890 902
16. L. Nathanson Mitoxantrone Cancer Treat. Rev. 11 1984 289 293
17. O. Neuhaus, B.C. Kieseier, and H.P. Hartung Mechanisms of mitoxantrone in multiple sclerosis - what is known? J. Neurol. Sci. 223 2004 25 27
18. N. Osheroff, A.H. Corbett, and M.J. Robinson Mechanism of action of topoisomerase II-targeted antineoplastic drugs Adv. Pharmacol. 29B 1994 105 126
19. Petermann, F., Korn, T., 2011. Cytokines and effector T cell subsets causing autoimmune CNS disease. FEBS Lett. 585, 37473757.
20. C.S. Raine The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion J. Neuroimmunol. 77 1997 135 152
21. S.C. Ridge Suppression of experimental allergic encephalomyelitis by mitoxantrone Clin. Immunol. Immunopathol. 35 1985 35 42
22. Solt, L.A., et al., 2011. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature 472, 491494.
23. I.U. Song Association between high-sensitivity C-reactive protein and risk of early idiopathic Parkinson's disease Neurol. Sci. 32 2011 31 34
24. M. Sospedra, and R. Martin Immunology of multiple sclerosis Annu. Rev. Immunol. 23 2005 683 747
25. B.D. Trapp Axonal transection in the lesions of multiple sclerosis N. Engl. J. Med. 338 1998 278 285
26. M. Veldhoen TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells Immunity 24 2006 179 189
27. J. Xu, and P.D. Drew Peroxisome proliferator-activated receptor-gamma agonists suppress the production of IL-12 family cytokines by activated glia J. Immunol. 178 2007 1904 1913
28. J. Xu, M.K. Racke, and P.D. Drew Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis J. Neurochem. 103 2007 1801 1810
29. J. Xu Liver X receptor agonist regulation of Th17 lymphocyte function in autoimmunity J. Leukocyte Biol. 86 2009 401 409
30. E. Zeinstra, N. Wilczak, and J. De Keyser Reactive astrocytes in chronic active lesions of multiple sclerosis express co-stimulatory molecules B7-1 and B7-2 J. Neuroimmunol. 135 2003 166 171